About us
Leading the field, not following
The ADC field continues to grow as ongoing technology innovations address past shortcomings for an improved probability of success.
Iksuda is at the forefront of this, developing class leading ADCs based on selecting the most clinically relevant combination of binder, conjugation chemistry, linker and payload mechanism.
Our best-in-class clinical-stage ADCs validate the tumor-selective payload activation approach, which we continue to innovate.
Our expanding early-stage ProAlk-ADC pipeline will offer new treatment choices for hard-to-treat cancers and help to address ADC sequencing – a major development challenge in the future
Our innovative research addresses all aspects of ADC technology including:
(i) We have developed a novel protein alkylator ('ProAlk') payload series - the first of its kind in the ADC field, and we continue to investigate novel payload mechanisms;
(ii) We are further optimising payload delivery via tailored linker formats;
(iii) We are expanding the utility of our bioconjugation platforms for higher drug loading where appropriate;
(iv) We are incorporating advanced binder screening and engineering into our research pipeline; evaluating biparatopic technologies, bi-specific conjugates and PK enhancement of Fc-variants.
Our purpose
We strive to bring better therapies to cancer patients, especially where current treatment options are limited. Our goal is to design and develop the best ADC for any given target through careful selection of the best combination of multiple components. We believe that the modular nature of the ADC modality provides an unparalleled opportunity for continued technologic improvement of next generation ADC therapeutics.
Our differentiated technology model
Advancing only the best ADCs toward the clinic. Iksuda’s later stage ADC pipeline is centered around known targets where clinical ADC benchmarks have shown clear evidence of target-dependent clinical activity, but where improvements in anti-cancer activity and/ or safety could result in a therapy with wider clinical utility. Clinical validation of novel linker formats enables the use of novel payloads, such as our ProAlk series, and a shift towards novel targets in our earlier-wave ADC programs.
Groundbreaking science delivered by expert teams
The quality of our people defines our business. Our people are given the freedom to innovate, alongside the guidance and support that comes with being part of a collaborative team.
